Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

To read yesterday’s edition of Five things for pharma marketers to know, click here.

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The largest study of its kind has revealed that the Pfizer-BioNTech Covid-19 vaccine presents considerably fewer problems for ...